CLDN18.2 ADC新星SKB315亮相ESMO

CPHI制药在线
Oct 14

关注并星标CPHI制药在线胃癌,作为我国发病与死亡率双高的恶性肿瘤,长期以来治疗手段有限,尤其对于HER2阴性患者,化疗与免疫治疗效果不尽如人意,中位生存期仅约一年。随着精准医疗的深入,CLDN18.2靶点逐渐成为胃癌治疗的新焦点。在2025年ESMO大会上,科伦博泰研发的CLDN18.2ADC药物SKB315首次公布临床数据,展现出优异的疗效与安全性,为晚期胃癌患者带来了新的曙光。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10